Uruguay opened registry to apply third and fourth doses of Pfizer coronavirus vaccine to population immunized with Sinovac

The Uruguayan Ministry of Health has announced that all people vaccinated with two doses of Sinovac will be able to register to receive a third and fourth booster injection of Pfizer.

Interested parties must enter their data to be assigned a shift after 90 days of completing the immunization schedule. Those who have received two injections of the preparation Sinovac will receive a third and a fourth dose of Pfizer.

“Moderate and severe immunocompromised patients must also be programmed and will be prioritized in the allocation of quotas. Those who have been vaccinated with two doses of Pfizer or Astrazeneca will receive a third Pfizer ”, the Ministry of Health reported in a statement.

Uruguay registered on Monday 160 new cases of coronavirus and six deaths, according to the daily report of the country’s National Emergency System (Sinae).

Since the start of the pandemic, 381,715 infections and 5,972 people died from COVID-19. There is currently 1,904 people with the disease, 48 of them were admitted to intensive treatment centers (ICS).

On the other hand, the country’s borders remain closed to non-residents, with exceptions for diplomatic, personal or economic and professional reasons, with the express authorization of the Executive.

Likewise, Uruguayan scientists announced that The first wave of COVID-19 infections the South American country suffered late last year was due to a local mutation of SARS-CoV-2.

The Institut Pasteur in Uruguay, based in Montevideo, reported in a statement that the P.6 variant was generated in that country, but was later moved by the P.1, also known as the Brazilian, which circulates predominantly among the Uruguayan population by what estimated that this country’s variant stopped producing infections since the end of April last year and has now disappeared.

The discovery of the Uruguayan variant was made by researchers from the Inter-institutional Working Group (GTI), which performs genomic surveillance. According to the studies of this team of scientists, the variant appeared in November 2020 and prevailed in number of infections until March 2021.

(With information from EFE)

KEEP READING: